DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Status: Recruiting
Location: See all (13) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Methicillin-resistant S. aureus bacteremia
Locations
Other Locations
Australia
Flinders Medical Centre
NOT_YET_RECRUITING
Bedford Park
Box Hill Hospital
RECRUITING
Box Hill
Monash Medical Campus (Monash Medical Centre + Jesse McPherson Private Hospital)
RECRUITING
Clayton
Concord Repatriation and General Hospital
RECRUITING
Concord
Royal Brisbane and Women's Hospital
RECRUITING
Herston
Fiona Stanley Hospital
NOT_YET_RECRUITING
Murdoch
John Hunter Hospital
NOT_YET_RECRUITING
Newcastle
Royal Melbourne Hospital
RECRUITING
Parkville
Royal Perth Hospital
NOT_YET_RECRUITING
Perth
Westmead Hospital
RECRUITING
Westmead
Canada
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
RECRUITING
Montreal
Newfoundland Health Services (Health Sciences Centre and St. Clare's Mercy Hospital)
RECRUITING
St. John's
Fraser Health Authority (Surrey Memorial Hospital)
RECRUITING
Surrey
Contact Information
Primary
Lina Petrella
lina.petrella@muhc.mcgill.ca
514-934-1934
Time Frame
Start Date: 2024-11-14
Estimated Completion Date: 2027-11
Participants
Target number of participants: 300
Treatments
Experimental: Daptomycin
Daptomycin given by injection at a dose determined by the treating clinicians but no less than 6mg/kg
Active_comparator: Vancomycin
Vancomycin given by injection at a dose determined by the treating clinicians to achieve a trough-based or AUC-based target
Related Therapeutic Areas
Sponsors
Leads: Todd C. Lee MD MPH FIDSA
Collaborators: The Peter Doherty Institute for Infection and Immunity, University of Melbourne